Exebacase in Addition to Daptomycin against MRSA

Exebacase is a lysin (cell wall hydrolase) with direct lytic activity against Staphylococcus aureus including methicillin-resistant S. aureus (MRSA). Time-kill analysis experiments illustrated bactericidal activity of exebacase-daptomycin against MRSA strains MW2 and 494. Furthermore, exebacase in addition to daptomycin (10, 6, and 4 mg/kg/day) in a two-compartment ex vivo pharmacokinetic/pharmacodynamic simulated endocardial vegetation model with humanized doses resulted in reductions of 6.01, 4.99, and 2.81 log(10) CFU/g (from initial inoculum) against MRSA strain MW2.

Automated summary

Exebacase is a lysin that shows lytic activity against Staphylococcus aureus, including MRSA. Time-kill analysis experiments demonstrate the bactericidal activity of exebacase-daptomycin combination against MRSA strains. Additionally, in an ex vivo pharmacokinetic/pharmacodynamic simulated model, exebacase in combination with daptomycin reduces CFU/g counts of MRSA strain MW2 effectively.